| Ms Jennifer J Williams, MS,CCC-SLP | |
|
7024 Palamar Ter, Lanham, MD 20706-2151 | |
| (240) 463-0392 | |
| Not Available |
| Full Name | Ms Jennifer J Williams |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 7024 Palamar Ter, Lanham, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164869350 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SLP000245 (District Of Columbia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Jennifer J Williams, MS,CCC-SLP 7024 Palamar Ter, Lanham, MD 20706-2151 Ph: (240) 463-0392 | Ms Jennifer J Williams, MS,CCC-SLP 7024 Palamar Ter, Lanham, MD 20706-2151 Ph: (240) 463-0392 |
News Archive
BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.
A new study, published this week in the International Journal of Health Services, found that older adults without health insurance in China were 35% less likely to receive needed inpatient care compared to those with job-based health insurance.
Having strong social connections has many benefits, from splitting the tab on a pizza to having someone with whom to binge watch Netflix.
Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been watched for signs or symptoms of disease progression and then treated with a combination of rituximab and chemotherapy or rituximab alone for select cases. Recent trials have suggested a role for treatment of asymptomatic patients with single-agent rituximab followed by additional periodic dosing, called "maintenance therapy."
› Verified 8 days ago
Yvonne Moulton, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9470 Annapolis Rd, Suite 416, Lanham, MD 20706 Phone: 301-577-4333 | |
Samantha J Cody, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4200 Parliament Pl Ste 550, Lanham, MD 20706 Phone: 240-245-4370 | |
Brittany Lark, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9470 Annapolis Rd, Suite 416, Lanham, MD 20706 Phone: 301-577-4333 | |
Maria Rivas, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9470 Annapolis Rd, 416, Lanham, MD 20706 Phone: 301-577-4333 Fax: 301-577-5180 | |
Anna Rebecca Miller, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8200 Good Luck Rd, Lanham, MD 20706 Phone: 301-552-2000 | |
Dr. Sandra Genevieve Combs, PH.D., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4819 Walden Ln Ste 4880, Lanham, MD 20706 Phone: 240-667-1423 Fax: 240-764-6764 |